Neuphoria TherapeuticsNEUP +5.18%32 Interest Coverage is No Debt (1) as of Mar. 2026, which is 100% below its 10-year median of 10,000.00. GuruFocus rates NEUP with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 377 Biotechnology companies, Neuphoria Therapeutics ranks better than 99.2% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Neuphoria Therapeutics's
Operating Income
for the
three
months ended in Mar. 2026 was $-0.83 Mil. Neuphoria Therapeutics's Interest Expense for the
three
months ended in Mar. 2026 was $0.00 Mil.
Neuphoria Therapeutics has no debt.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Neuphoria Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.
(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Neuphoria Therapeutics's Interest Coverage or its related term are showing as below:
NEUP'
s Interest Coverage Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt
NEUP's Interest Coverage is ranked better than 99.2% of 377
companies
in the Biotechnology industry
Industry Median: 106.07
vs NEUP: No Debt
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Neuphoria Therapeutics Interest Coverage Related Terms
Neuphoria Therapeutics Interest Coverage Historical Data
* Premium members only.
The historical data trend for Neuphoria Therapeutics's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
NEUP vs CRVO, IGC, SNSE: Interest Coverage Comparison
For the Biotechnology subindustry, Neuphoria Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuphoria Therapeutics Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neuphoria Therapeutics's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Neuphoria Therapeutics's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of No Debt <sup>(1)</sup> mean?
Neuphoria Therapeutics (NEUP) has a Interest Coverage of No Debt (1) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Neuphoria Therapeutics and its competitors. This is 100% below median its historical median of 10,000.00. Over the past decade, Neuphoria Therapeutics' Interest Coverage has ranged from 10,000.00 to 10,000.00. According to the industry distribution chart, Neuphoria Therapeutics ranks #3 out of 377 companies in the Biotechnology industry, placing it in the top 0.8%.
Is Neuphoria Therapeutics' Interest Coverage too high?
Neuphoria Therapeutics' current Interest Coverage of No Debt (1) is 100% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 10,000.00 to a high of 10,000.00. Based on the distribution chart, Neuphoria Therapeutics ranks #3 out of 377 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Neuphoria Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Neuphoria Therapeutics' Interest Coverage compare to CRVO and IGC?
According to the Biotechnology industry distribution chart, Neuphoria Therapeutics ranks #3 out of 377 companies for Interest Coverage. This places Neuphoria Therapeutics in the top 1% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 106.07. Historically, Neuphoria Therapeutics' own Interest Coverage has ranged from 10,000.00 to 10,000.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Neuphoria Therapeutics and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuphoria Therapeutics's current Interest Coverage is No Debt (1), which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuphoria Therapeutics stock overvalued right now?
Neuphoria Therapeutics (NEUP) has a current Interest Coverage of No Debt (1). The current Interest Coverage is No Debt (1), which is 100% below median its 10-year median of 10,000.00. Neuphoria Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Neuphoria Therapeutics (NEUP), the current Interest Coverage is No Debt (1) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
32GF Score
Get the complete analysis for NEUP
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEUP has been successfully added to your 
